Premium
Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report
Author(s) -
Schein Philip S.,
Lavin Philip T.,
Moertel Charles G.,
Frytak Stephen,
Hahn Richard G.,
O'Connell Michael J.,
Reitemeier Richard J.,
Rubin Joseph,
Schutt Allen J.,
Weiland Louis H.,
Kalser M.,
Barkin J.,
Lessner H.,
MannKaplan R.,
Redlhammer D.,
Silverman M.,
Troner M.,
Douglass H. O.,
Milliron S.,
Lokich J.,
Brooks J.,
Chaffe J.,
Like A.,
Zamcheck N.,
Ramming K.,
Bateman J.,
Spiro H.,
Livstone E.,
Knowlton A.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197807)42:1<19::aid-cncr2820420103>3.0.co;2-4
Subject(s) - methotrexate , medicine , chemotherapy , gastroenterology , randomized controlled trial , carcinoma , clinical trial , oncology
Sixty‐six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin‐D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin‐D responded. The duration of responses ranged from 43–64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin‐D therapy.